Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.
暂无分享,去创建一个
H. Engelhard | S. Brem | S. Gately | K. Eidsvoog | S. Takano | M. Neville | J. Gross | W. Herblin | M. Perricone
[1] C. Stein,et al. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. , 1993, Cancer research.
[2] K. Danø,et al. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. , 1993, The Journal of biological chemistry.
[3] J. McCubrey,et al. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. , 1993, Journal of immunological methods.
[4] B. Teicher,et al. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. , 1992, Cancer research.
[5] D. Collins,et al. Inhibition of angiogenesis by suramin. , 1992, Cancer research.
[6] F. Sola,et al. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. , 1992, British Journal of Cancer.
[7] G. Peters,et al. The effect of schedule, protein binding and growth factors on the activity of suramin , 1992, International journal of cancer.
[8] S. Steinberg,et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] K. Robbins,et al. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. , 1992, The Journal of clinical investigation.
[10] S. Lelièvre,et al. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[11] E. Reed,et al. Suramin in advanced platinum-resistant ovarian cancer. , 1992, European journal of cancer.
[12] J. Kim,et al. Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. , 1991, The Journal of urology.
[13] R. Danesi,et al. A pilot study of suramin in the treatment of metastatic renal cell carcinoma , 1991, Cancer.
[14] S. Brem,et al. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. , 1990, The American journal of pathology.
[15] E. Kohn,et al. Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. , 1990, Cancer research.
[16] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[17] J. Gray,et al. Double labeling with iodo- and bromodeoxyuridine for cell kinetics studies. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[18] D. Rifkin,et al. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis , 1988, The Journal of cell biology.
[19] M. Fukushima,et al. Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin. , 1988, European journal of biochemistry.
[20] S. Kennedy,et al. Antiproliferative effects of suramin on lymphoid cells. , 1987, Cancer research.
[21] R. Coffey,et al. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells , 1987, Journal of cellular physiology.
[22] J. Fiddes,et al. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth , 1987, Nature.
[23] S. Szabó,et al. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. , 1985, Science.
[24] D. Moscatelli,et al. Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[25] A. Granelli‐Piperno,et al. A study of proteases and protease-inhibitor complexes in biological fluids , 1978, The Journal of experimental medicine.
[26] D. Jodrell,et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. , 1993, Journal of the National Cancer Institute.
[27] G. Wilding,et al. Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates , 1993, The Prostate.
[28] H. Scher,et al. Use of adaptive control with feedback to individualize suramin dosing. , 1992, Cancer research.
[29] S. Brem. The Development of Therapeutic Angiosuppression: Problems and Progress , 1992 .
[30] H. Engelhard,et al. Simultaneous quantification of c-myc oncoprotein, total cellular protein, and DNA content using multiparameter flow cytometry. , 1991, Cytometry.
[31] L. Vrba,et al. Inhibition of angiogenesis with combination treatments of angiostatic steroids and suramin. , 1991, International journal of radiation biology.
[32] J. Folkman,et al. Angiogenic factors. , 1987, Science.